Prostate Cancer Trial, Recruiting NCT06863090 Sponsor: East and North Hertfordshire NHS Trust Condition: Prostate Cancer
Back to Prostate Cancer

Prostate Cancer Trial, Recruiting

NCT06863090
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • Adults aged 18 years or older
  • People receiving a specific type of internal radiation treatment called HDR brachytherapy (using a radioactive source called iridium-192), either on its own or combined with external radiation, for prostate cancer that has been confirmed by biopsy or imaging — including cancer that has come back in the same area
  • People receiving the same type of internal radiation treatment for certain gynaecological cancers, including cervical, vulval, vaginal, or uterine (endometrial) cancer at various stages — including cases where the cancer has returned — as determined appropriate by a specialist medical team
  • People with a general health and activity level rated as reasonably functional (rated 0, 1, or 2 on a standard medical scale, meaning able to carry out at least some daily activities)

Who may not be able to join:

  • People who have previously had brachytherapy (internal radiation) to the same area of the body being treated
  • People who are not able to give their informed consent to participate
  • People who are not able to receive regional or general anaesthesia (numbing or sedating medication used during the procedure)
  • People with certain medical conditions, including blood clotting disorders, a history of another separate cancer, a known allergy or sensitivity to any materials used in the study, or a history of or current abnormal connections between organs (fistulae)
  • People who are not able to understand the study information in English
  • People who have taken part in another interventional research study within the last 6 months, or who are currently participating in one

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Peter Hoskin, East and North Hertfordshire NHS Trust

Phone: 0203 826 2020

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
East and North Hertfordshire NHS Trust
Registry
ClinicalTrials.gov
Start date
3 March 2025
Est. completion
1 March 2026

Where this trial is recruiting

🇬🇧 United Kingdom

Primary endpoints

To assess the feasibility of in vivo dosimetry in HDR brachytherapy and compare the calculated dose against measured dose

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov